New drug trial aims to stop liver Cancer's return after surgery
NCT ID NCT06851104
Summary
This study tested whether a drug called cadonilimab could help prevent liver cancer from coming back after successful surgery. It focused on patients at high risk of their cancer returning. The trial was terminated early and enrolled 45 participants to assess safety and effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.